KR20090003282A - Anti-fat-accumulation composition - Google Patents

Abstract

Disclosed is an anti-fat-accumulation composition comprising a sugar alcohol and an oligosaccharide at a ratio of 1:3 to 1:20 by weight, preferably 1:7 to 1:10 by weight. A preferred example of the sugar alcohol is xylitol. A preferred example of the oligosaccharide is palatinose. The composition is excellent in taste and safety and shows a high anti-fat-accumulating activity with high reliability.

Description

Antifat accumulation composition {ANTI-FAT-ACCUMULATION COMPOSITION}

The present invention relates to a composition having an antifat accumulation effect.

Obesity prevention and treatment are very important tasks in maintaining and promoting health. Obesity causes type 2 diabetes, hypertension, hyperlipidemia and the like. These diseases are also basic diseases such as stroke and ischemic heart disease. At present, these diseases are interpreted as a series of metabolic abnormalities based on insulin resistance caused by obesity. Among them, the number of diabetics is known to have increased by 2.5 million people in the last five years to include 16.2 million, including the diabetic reserve group, and it is no exaggeration to say that it is a national disease. As described above, since obesity is associated with major diseases, the prevalence and increase in obesity have been attracting attention in developed countries. It is the same situation in developing countries, and it is already estimated that the type 2 diabetes leprosy rate will increase dramatically in the next 10 years due to the prevalence and increase of obesity. In addition, recent findings suggest that an increase in postprandial blood sugar or insulin concentrations is a risk factor for diabetes, heart disease, and cancer, and therefore is the concept that reducing postprandial blood sugar or insulin levels is not useful for the prevention or treatment of such diseases? (ILCI JAPAN Sugar Research Group, International Conference Lecture "International Symposium Sugar and Health," Genpakusha, published December 2003). The three major causes of Japanese death are cancer, heart disease, and stroke, but one of the causes of circulatory diseases caused by heart disease and stroke is atherosclerosis. Cholesterol is known as a risk factor for atherosclerosis, but recent studies have found that obesity (especially visceral fat) causes various lifestyle diseases, making it more susceptible to atherosclerosis. From this, preventing obesity, which can be said to be a factor causing various diseases, is also useful for healthy people.

Until now, as an agent for inhibiting obesity, gut lipase inhibitors (Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M, Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.European Multicentre Orlistat Study Group., Lancet, 352, pp. 167-172 (1998)], Appetite suppressants (Said Tomoaki, Mizuma Hiroshi, Suguzo, Hayashi Yozo, Appetite suppressant margin stones On blood pressure, carbohydrate metabolism and lipid metabolism, medical treatment and new drugs, 32 (9), pp.1653-1660 (1995)]), and foods for inhibiting obesity include proteins, lipids and sugars in specific ratios. Effects of Long-term Intake of Containing Compositions (Japanese Patent No. 3545760) or Hydroxycitric Acid (Genot Onomura Genta, Sea Bream Hironori, Ryuichi Otsuka, Keikawa Kawabata, Garcinia Extract) on Body Fat Mass in Humans , health Nutritional Food Research, 3 (4), pp.23-30 (2000)]), capsaicin (KAWADA T, HAGIHARA K, IWAI K, Effects of capsaicin on lipid metabolism in rats fed a high fat diet., J Nutr , 116 (7), pp.1272-1278 (1986)]), but anti-fat accumulation compositions that can be safely consumed over a long period of time without damaging the taste even when added to various foods and drugs It became.

Xylitol is a kind of sugar alcohol and is used as a substitute for sugar. It has been found that xylitol does not elevate blood glucose levels or insulin secretion because it is absorbed in a pathway that does not pass through insulin (Geoffrey Livesey, Health potential of polyols as sugar replacers, with emphasis on low glycemic properties., Nutrition Research Reviews , 16, pp 163-191 (2003)]. In addition, the effect of anti-caries (as a good sugar for teeth, etc.) has been reported (Geoffrey Livesey, Health potential of polyols as sugar replacers, with emphasis on low glycemic properties., Nutrition Research Reviews., 16, pp 163) -191 (2003)], as well as improving osteoporosis (Mattila PT, Svanberg MJ, Jamsa T, Knuuttila ML, Improved bone biomechanical properties in xylitol-fed aged rats., Metabolism, 51 (1), pp.92-). 96 (2002)]), preventing otitis media (M Niemela, 0 Pihakari, T Pokka, M Uhari, M Uhari, Pacifier as a Risk Factor for Acute Otitis Media: A Randomized, Controlled Trial of Parental Counseling., PEDIATRICS, 106 (3), pp. 483-488 (2000)], which is of interest to the various potential health benefits, but has not yet been reported on the effect of fat accumulation inhibition.

Palatine is a type of oligosaccharide. Also known as isomaltulose, it is used in sweeteners and the like. Palatinose taken orally is broken down by isomaltase in the digestive tract. In addition, isomaltase, panos, and isomaltrios digested with isomaltase compete with the digestion of palatinose, so it is known that digestive absorption is inhibited by the intake of palatinose (Japanese Journal of Nutrition and Food Science, 36) (3), pp. 169-173 (1983)] In addition, the rate of decomposition of palatinose is about 1/5 of sucrose, thereby suppressing a sudden increase in blood glucose value and blood insulin concentration.

In addition, a blood sugar synergistic inhibitory effect and a fat accumulation inhibitory effect when ingested together with a sugar that is decomposed and metabolized without passing through isomaltases such as sucrose and glucose have also been reported (Japanese Patent Laid-Open No. 2004-315499). However, there was no report of synergistic effects when combined with sugar alcohols such as xylitol.

<Start of invention>

An object of the present invention is to find an anti-fat accumulation composition having higher activity, which is excellent in taste and safety.

The present invention has been made to solve the above problems. The present inventors have reported that palatinose and / or trehalose in saccharides are effective as one of the components for inhibiting blood sugar rise and body fat accumulation with respect to the nutritional composition for controlling blood sugar values shown in Japanese Patent No. 3545760, but also the blood sugar value In the nutritional composition for control, other components that exhibit an inhibitory effect on blood sugar elevation and fat accumulation were also studied. As a result, it has been found that xylitol contained in the nutritional composition for controlling blood sugar values contributes to the exertion of the anti-fat accumulation effect in vivo.

In addition, the present inventors have found that sugar alcohols such as xylitol, or a mixture of sugar alcohols and oligosaccharides (for example, palatinose) at a predetermined ratio have an anti-fat accumulation effect and have completed the present invention.

That is, the present invention

[1] anti-fat accumulation composition containing sugar alcohol,

[2] The composition for antifat accumulation according to the above [1], containing an oligosaccharide;

[3] The composition for anti-fat accumulation according to the above [2], wherein the oligosaccharide is a heterooligosaccharide.

[4] The composition for anti-fat accumulation according to the above [3], wherein the heterooligosaccharide is a sucrose structural isomer.

[5] The composition for anti-fat accumulation according to any one of [2] to [4], wherein the sucrose structural isomer is palatinose;

[6] The composition for anti-fat accumulation according to any one of [2] to [5], wherein the sugar alcohol and the oligosaccharide are contained in a weight ratio of 1: 3 to 1:20.

[7] The composition for anti-fat accumulation according to any one of [1] to [6], wherein the sugar alcohol is xylitol;

[8] a pharmaceutical product for preventing and / or treating fat accumulation, comprising the anti-fat accumulation composition according to any one of the above [1] to [7] as an active ingredient;

[9] A food and drink for preventing and / or treating fat accumulation, comprising the anti-fat accumulation composition according to any one of [1] to [7].

[10] Use of the anti-fat accumulation composition according to any one of the above [1] to [7] for the manufacture of a pharmaceutical product for fat accumulation and / or treatment, or a food and drink for fat accumulation prevention and / or treatment,

[11] A method for preventing and / or treating fat accumulation by administering the anti-fat accumulation composition according to any one of [1] to [7].

To provide.

Since the anti-fat accumulation composition of the present invention has an effect of inhibiting the accumulation of blood fat, body fat, visceral fat, and subcutaneous fat, it is used for the prevention and / or treatment of obesity, type 2 diabetes, hypertension, hyperlipidemia, stroke, ischemic heart disease, and the like. useful. That is, it is possible to add to food and beverages, medicines, there is an advantage that can easily provide an anti-fat accumulation composition excellent in taste and safety.

1 shows the change in the average body weight g of each group during the test period in Example 1. FIG. Mean value ± standard deviation (n = 9) is shown. Δ denotes a control group and ■ denotes an Xyl group.

FIG. 2 shows the results of the X-ray CT apparatus in Example 1 before the test start (6 days before the test start date), during the test period (25 days after the test start date), and after the test (53 days after the test start date). The percentages of the calculated relative muscle mass (g / g body weight) and relative fat mass (g / g body weight) are shown in percentage. Mean value ± standard deviation (n = 9) is shown. □ represents the control group and ■ represents the Xyl group. *: p <0.05 (t-test of Student).

Fig. 3 shows the relative fat mass (g / g body weight) of the peri testis, posterior peritoneum and mesentery at the time of necropsy (58 days after the start of the test) in Example 1 in percentage. Mean value ± standard deviation (n = 9) is shown. □ represents the control group and ■ represents the Xyl group. *: p <0.05 (t-test of the student).

4 shows the change in the average body weight g of each group during the test period in Example 2. FIG. Mean value ± standard deviation (n = 6) is shown. Δ represents a control group, and Δ represents a palatinose group.

Fig. 5 shows the relative fat mass (g / g body weight) of the peri testicular and posterior peritoneum at autopsy in Example 2 (66 days after the start of the test) in percentage. Mean value ± standard deviation (n = 6) is shown. □ indicates a control group and ■ indicates a palatinose group. **: p <0.01 (student's t test).

FIG. 6 shows the transition of the average body weight g of each group during the test period in Example 3. FIG. Mean value ± standard deviation (n = 6) is shown. Δ represents a control group, and ◆ represents an Xyl group. *: p <0.05 (t-test of the student).

FIG. 7 shows the results of the X-ray CT apparatus in Example 3 before the test start (6 days before the test start date), during the test period (28 days after the test start date), and at the end of the test (56 days after the test start date). The percentages of the calculated relative muscle mass (g / g body weight) and relative fat mass (g / g body weight) are shown in percentage. Mean value ± standard deviation (n = 6) is shown. □ represents Xyl (-) group, and ■ represents Xyl (+) group. *: p <0.05 (t-test of the student).

Fig. 8 shows the relative fat mass (g / g body weight) of the peri testis, posterior peritoneum and mesentery at the time of necropsy (60 days after the start of the test) in Example 3 in percentage. Mean value ± standard deviation (n = 6) is shown. □ represents Xyl (-) group, and ■ represents Xyl (+) group. **: p <0.01 (student's t test)

Fig. 9 shows the change in the average body weight g of each group during the test period in Example 4. Mean value ± standard deviation (n = 6) is shown. □ indicates a control group, ◆ indicates a palatinose group, △ indicates a low xylitol low dose group, ▲ indicates a combined low dose group, ○ indicates a high xylitol high dose group, and ● indicates a combined high dose group. *: vs. control, p <0.05 (Tukey-Kramer multiple comparison test).

FIG. 10 shows X in Example 4 before the start of the test (7 or 6 days before the start of the test), mid-test (28 or 29 days after the start of the test), and at the end of the test (56 or 57 days after the start of the test). The percentages of relative muscle mass (g / g body weight) and relative fat mass (g / g body weight) obtained from the results of the line CT device are shown in percentage. Mean value ± standard deviation (n = 6) is shown. *, **: vs. control, p <0.05, 0.01 (tucky-cramer multiple comparison test)

Fig. 11 shows the relative fat mass (g / g body weight) around the testis at the time of necropsy (60 days after the start of the test) in Example 4 in percentage. Mean value ± standard deviation (n = 6) is shown. **: vs. control, p <0.01 (tucky-cramer multiple comparison test)

12 shows the relative fat mass (g / g body weight) of the retroperitoneum at autopsy in Example 4 (60 days after the start of the test) in percentage. Mean value ± standard deviation (n = 6). *, **: vs. control, p <0.05, 0.01 (tucky-cramer multiple comparison test)

FIG. 13 shows the relative fat mass (g / g body weight) of the mesentery at the time of necropsy (60 days after the start of the test) in Example 4 as a percentage. Mean value ± standard deviation (n = 6) is shown. *, **: vs. control, p <0.05, 0.01 (tuki-cramer multiple comparison test).

Best Mode for Carrying Out the Invention

Hereinafter, the present invention will be described in detail. However, this invention is not limited to the following preferable embodiment, It can change freely within the scope of the present invention.

Sugar alcohol is a generic term for a compound having a structure in which a sugar aldehyde group is reduced to become an alcohol. When taken orally with sugar alcohol, about half is absorbed into the body, and the rest reaches the large intestine and is used for fermentation of intestinal bacteria (Geoffrey Livesey, Health potential of polyols as sugar replacers, with emphasis on low glycemic properties., Nutrition Research Reviews., 16, pp 163-191 (2003)]. Moreover, even when absorbed, they are attracting attention as low-calorie sweeteners because they have different metabolic pathways and less energy.

Although the sugar alcohol used for the antifat accumulation composition of this invention is not specifically limited, For example, xylitol, sorbitol, maltitol, erythritol, lactitol, mannitol, paratinite (reduced palatinose), etc. are mentioned. .

Among these, xylitol can not only reliably obtain synergistic anti-fat accumulation effect by adding a small amount to oligosaccharides (for example, palatinose), but also has a refreshing sweetness and refreshing aftertaste. It is preferably used in view of expectation.

These sugar alcohols may be any of natural derived products, chemical synthetic products, synthetic products by enzymes or microorganisms, and / or may be foods containing many of them. In addition, these sugar alcohols can be used individually or in combination of 2 or more types.

Xylitol is also a type of polyhydric alcohol and is also called xyllo-pentitol or xylitol, trans, clinic, utreat, or kilit. Molecular weight 152.146, Cas. No. 87-99-0, it is used in tonics, carbohydrate metabolism agents, nutrients, and sugar substitutes. It is known to be contained in very small amounts in many plants, such as strawberries, raspberries, and cauliflower. It is also commercially produced from hardwood or birch wood residues. Like fructose, xylitol is very soluble in water and can withstand heating or freezing. Xylitol is almost the same sweetness as fructose and is a fresh sweetness in aqueous solution. Its sweetness is reduced by heating or addition of acidity (John D. Brunzell, Use of fructose, sorbitol, or xylitol as a sweetener in diabetes mellitus., J. The American Dietetic Association., 73, pp. 499- 506 (1978)]. Since the heat of dissolution in water is -36.6 cal / g, it is possible to enjoy a cool feeling at the time of oral ingestion. Xylitol absorbed by oral intake is converted into D-xylose by xylitol dehydrogenase, and is metabolized into carbon dioxide and water by the pentose phosphate cycle and so on, and has little effect on blood glucose values. The energy conversion factor is 3 kcal / g (Geoffrey Livesey, Health potential of polyols as sugar replacers, with emphasis on low glycemic properties., Nutrition Research Reviews., 16, pp 163-191 (2003)). However, it has also been reported to have α-glucosidase inhibition (Japanese Patent No. 2790610.) Therefore, it is difficult to raise insulin secretion and blood glucose values after ingestion. The indexes of glycemic index and insulin secretion, which are indices, are 13 and 11, which is very low compared to 100 and 100 of glucose or 65 and 43 of sucrose. It is also known to be anti-carious because it is low (Geoffrey Livesey, Health potential of polyols as sugar replacers, with emphasis on low glycemic properties., Nutrition Research Reviews., 16, pp 163-191 (2003)). In addition, improvement of osteoporosis (M Niemela, O Pihakari, T Pokka, M Uhari, M Uhari, Pacifier as a Risk Factor for Acute Otitis Media: A Randomized, Controlled Trial of Parental Counseling., PEDIATRICS, 106 (3). , pp.483-488 (2000)]), and the prevention of otitis media (the literature [Journal of the Nutrition and Food Society of Japan, 36 (3), pp.169-173 (1983)]). It is characterized by its excellent suppression, low extinguishing rate, anti-carious and penetrating pressure, etc. and interests in its usefulness for various potential health, but no anti-fat accumulation effect has been reported.

The oligosaccharide used for the antifat accumulation composition of this invention is not limited in the kind, It may be any of homo oligosaccharide and hetero oligosaccharide.

Examples of homooligosaccharides are isomaltose, kojibiose, nigerose, isomaltotriose, isomaltotetraose, panos, maltooligosaccharides, xyloligosaccharides, inolo oligosaccharides, isomaltoligosaccharides, hymaltotriose syrups, and cello oligosaccharides. , Trehalose, genthio oligosaccharides, panos, nigerolo oligosaccharides and the like.

Examples of heterooligosaccharides include palatinose, fructooligosaccharides, galactoligosaccharides, transition galactooligosaccharides, soy oligosaccharides, raffinose, and palatinose syrups (syrups containing trehalose and palatinose), paratinose oligosaccharides, lacto oligosaccharides, glucosyl sucrose and lactose. Loose, trehalose, pectin oligosaccharides and the like. Among them, sucrose structural isomers such as palatinose and trehalose can be preferably used.

On the other hand, these oligosaccharides may be any of natural derived products, chemical synthetic products, synthetic products by enzymes and microorganisms, and / or may be foods containing a large number of them. In addition, these oligosaccharides can be used individually or in combination of 2 or more types.

Among the oligosaccharides, palatinose is able to reliably obtain synergistic anti-fat accumulation effect by adding a small amount of sugar alcohol (for example, xylitol), and moderately absorbs digestion after meal, thereby suppressing the effect of raising blood sugar. It can obtain, and is used preferably at the point which 100% is absorbed.

Pallatinose is a disaccharide in which glucose and fructose are bound by α-1,6 molecules, each of which is a structural isomer of sucrose, and 6-O- (α-D-glucopyranosyl) -D-fructose or isomasilose, isomaltulose Also called. Molecular weight 342.297, Cas. No.13718-94-0, used for sweeteners and the like. Contains very small amounts of honey and sugar cane. In addition, sucrose may be prepared by transferring α-1,2 bonds to α-1,6 bonds by applying α-glucosyltransferase of Protaminobacter rubrum origin. Palatinos sweetness is similar to sucrose, but sweetness is about half that of sucrose. It is known to have anti-caries because it does not serve as a substrate for insoluble glucan synthesis of caries, such as mutans, and competitively inhibits insoluble glucan synthesis from sucrose (Nakakuki T, Trends in Glycoscience and Glycotechno1ogy, 15 (82), pp. 57-64 (2003)]. Orally consumed palatinose is broken down by isomaltase in the digestive tract. In addition, isomaltase, panos, and isomaltrios digested with isomaltase compete with the digestion of palatinose and are known to inhibit digestive absorption by the ingestion of palatinose. (3), pp. 169-173 (1983). Calories are 4 kcal / g. The rate of degradation of palatinose is about 1/5 of sucrose, thereby suppressing a sharp rise in blood glucose values and blood insulin levels. On the other hand, the obesity mechanism has a structure in which lipoprotein lipase of adipose tissue is activated by insulin, and triglycerides in the blood are rapidly injected into the adipose tissue and accumulated as body fat. Since palatinose has a slow digestive absorption after oral ingestion and low secretion of insulin secretion, it is thought that the fat ingested is difficult to be absorbed into the adipose tissue without increasing the activity of lipoprotein lipase. A cumulative inhibitory effect appeared (Catalatin's catalogue, Mitsui Seito Kabushiki Kaisha). In addition, a blood sugar synergistic inhibitory effect and a fat accumulation inhibitory effect when ingested together with a sugar that is decomposed and metabolized without passing through isomaltases such as sucrose and glucose have also been reported (Japanese Patent Laid-Open No. 2004-315499). However, there are no reports of synergistic effects when combined with sugar alcohols such as xylitol.

It was confirmed by the in vivo body fat accumulation test that the anti-fat accumulation composition of the present invention is useful as a composition effective for the prevention and / or treatment of fat accumulation.

The present inventors have reported that palatinose and / or trehalose in saccharides are effective as one of the components for inhibiting blood sugar rise and body fat accumulation with respect to the nutritional composition for controlling blood sugar values shown in Japanese Patent No. 3545760, but also the blood sugar value In the nutritional control composition, other components that exhibit blood sugar elevation and anti-fat accumulation effects were also examined.

First, xylitol was partially substituted with sucrose in a tablet feed for mouse and rat to prepare a tablet for xylitol-added tablets, and mice were freely ingested for 2 months. As a result, the mice fed the xylitol-added tablets were significantly lower in relative fat mass at necropsy compared to the mice provided with tablets without xylitol. This suggests that xylitol has an antifat accumulation effect.

In addition, a test was conducted in which rats were freely ingested for 2 months, using a control formula containing 40% sucrose in a tablet feed for mouse and rat and a test formula added with palatinose instead of sucrose. As a result, the rats provided with the test formula were significantly lower in relative fat amount at necropsy compared to the rats provided with the control formula. From this, the anti-fat accumulation effect of palatinose was demonstrated.

In addition, the degree of anti-fat accumulation effect was compared between the feed containing a small amount of xylitol and the feed containing no palatinose. The weight ratio of xylitol to palatinose when xylitol was added to the feed containing palatinose was 1.0: 5.5 to 1.0: 15.6, although the amount of xylitol was clearly less than that of palatinose. In feed compositions containing xylitol, more significant anti-fat accumulation effects were found. That is, it was disclosed that xylitol and palatinose exerted a synergistic effect on the inhibition of fat accumulation.

Thus, sugar alcohols (xylitol, sorbitol, maltitol, erythritol, lactitol, mannitol, paratinite (reduced palatinose), etc.), or sugar alcohols and oligosaccharides (palatinose, isomaltose, cozibiose, nigerose) , Isomaltriotriose, panos, isomaltetotraose and the like) can also be expected to be effective as compositions for anti-fat accumulation similarly.

Anti-fat accumulation composition of the present invention is a composition having the effect of inhibiting the accumulation of blood fat, body fat, visceral fat, subcutaneous fat, diseases based on obesity, complications of obesity, diabetes mellitus, syndrome X, insulin resistance, (Hyperinsulinemia, etc.), hypertension, hyperlipidemia, arteriosclerosis, hyperuricemia, gout, fatty liver, gallstones, respiratory diseases (sleep apnea syndrome, Pickwick syndrome, etc.), circulatory system diseases, (stroke, ischemic heart disease, angina pectoris) , Myocardial infarction, congestive heart failure, diffuse vascular coagulation syndrome, cardiac hypertrophy, bone and joint disorders (deformed arthrosis, lumbar dislocation, lumbar lordosis, etc.), infertility, menstrual abnormalities, uterine cancer, neurological diseases (sciatic neuralgia, etc.) ), And application to the prevention and / or treatment of chronic nephritis. That is, it is possible to add to food and beverages, medicines, there is an advantage that can easily provide an anti-fat accumulation composition excellent in taste and safety.

The content of the sugar alcohol or oligosaccharide contained in the anti-fat accumulation composition of the present invention is not particularly limited because it depends on the form, formulation, symptoms, weight, use, etc., but the sugar alcohol is applied to the anti-fat accumulation of the present invention It is preferable that it is the range of 0.8% (w / w)-100% (w / w) in a composition, and oligosaccharide is 1.0% (w / w)-100% (w / w) in the composition for antifat accumulation of this invention. It is preferable that it is the range of. Sugar alcohols and oligosaccharides may be used alone or in combination. When using together, sugar alcohol and oligosaccharide can be used in combination in arbitrary ratio, From a viewpoint of the effect by combined use, Preferably it is a weight ratio 1: 3-1: 20, More preferably, it is a weight ratio 1: 4-1: 1. 15, more preferably 1: 5 to 1:12 by weight, particularly preferably 1: 7 to 1:10 by weight.

When the weight ratio is 1: 5 to 1:12 (particularly 1: 7 to 1:10), the effect of the combination of the sugar alcohol and the oligosaccharide more reliably (in other words, the difference in the effect between the ingested individuals is small, With small standard deviations).

In the present invention, the total intake of sugar alcohol and oligosaccharide is per person per day, preferably 3 to 200 g, more preferably 7 to 160 g, particularly preferably 14 to 130 g.

The number of times of ingestion per day of the anti-fat accumulation composition of the present invention is preferably 1 to 5 times, but can be appropriately changed according to symptoms and purposes. It can also be taken continuously, such as cervical administration.

The energy ratio of the oligosaccharide in the total energy amount of the sugar in the antifat accumulation composition of the present invention is preferably 60 to 80%.

The compounding amount of the anti-fat accumulation composition of the present invention into medicines or food and drink is not particularly limited because it varies depending on the form, formulation, symptoms, weight, use, etc., but may be blended in an amount of 0.01 to 100% (w / w). And, preferably, 0.1 to 100% (w / w), and more preferably 1.0 to 100% (w / w).

The daily intake of the medicine or food or drink of the anti-fat accumulation composition of the present invention is not particularly limited since it depends on age, symptoms, weight, use, etc., but may be ingested in a range of 0.1 to 10000 mg / kg, preferably 1.0 to 5000 mg / kg body weight, more preferably 10.0 to 3500 mg / kg body weight.

The composition for anti-fat accumulation of the present invention can be used in any form of medicines or food and drink. For example, it is expected to treat and / or prevent fat accumulation by directly administering as a medicament, or directly ingested as a special purpose food or nutritional functional food such as a specific health food. Various types of foods (milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crust, powdered milk powder, liquid foods, sick foods, nutritional foods), regardless of the form of liquids, pastes, solids and powders , Frozen foods, processed foods, and other commercially available foods).

The food containing the composition for anti-fat accumulation of the present invention can be used by mixing water, protein, sugar, lipids, vitamins, minerals, organic acids, organic bases, juices, flavors and the like. As the protein, for example, whole milk powder, skim milk powder, partially skim milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, β-lactoglobulin animal and plant proteins such as α-lactoalbumin, lactoferrin, soy protein, egg protein, meat protein, and degradation products thereof; And various milk-derived components such as butter, oily minerals, creams, whey, nonprotein nitrogen, sialic acid, phospholipids, and lactose. It may also contain peptides or amino acids such as casein phosphopeptide, arginine and lysine. Examples of the saccharides include sugars, processed starches (except dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), plant fibers, and the like. As a lipid, For example, animal fats and oils, such as these fractionation oil, hydrogenated oil, and transesterified oil; And vegetable oils such as palm oil, safflower oil, corn oil, rapeseed oil, palm oil, fractionated oils thereof, hydrogenated oil, and transesterified oils. As vitamins, for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline, folic acid Etc. As minerals, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, etc. are mentioned, for example. As an organic acid, malic acid, citric acid, lactic acid, tartaric acid, etc. are mentioned, for example. In the manufacture of the food-drinks containing the composition for anti-fat accumulation of the present invention, these may be any of natural products derived from synthetic products, and / or may be used as a raw material. These components can be used in combination of 2 or more type. The food form may be either solid or liquid. It may also be a gel or the like.

When using the anti-fat accumulation composition of this invention as a medicine, it can administer in various forms. Examples thereof include oral administration by tablets, capsules, granules, powders, syrups, and the like, but may also be in other forms such as cervical or intravenous. These various formulations can be formulated according to conventional methods using known auxiliaries which are commonly used in the field of pharmaceutical formulation technology such as excipients, binders, disintegrants, lubricants, odorants, dissolution aids, suspending agents, coating agents etc. . It may also contain an appropriate amount of calcium. In addition, an appropriate amount of vitamins, minerals, organic acids, sugars, amino acids, peptides and the like may be added.

On the other hand, all the prior art documents cited in the present specification are incorporated herein by reference.

Hereinafter, although an Example is given and demonstrated this invention, this invention is not limited by this.

Example 1 (Measurement of Anti-fat Accumulation Effect of Xylitol)

(1) materials and methods

C57BL / 6 mice (male, 5 week old, 6 week old test start, n = 9 / group) were divided into groups to prepare a control group (hereinafter also referred to as AIN group) and Xyl group. The control group received AIN-93M feed as a test meal. In the Xyl group, a part of the sucrose contained in the AIN-93M feed was replaced with xylitol (hereinafter also referred to as Xyl) to provide a xylitol-added AIN-93M feed as a test meal. On the other hand, in the xylitol-added AIN-93M feed, the added Xyl amount of sucrose was subtracted, and the sugar mass in the test formula was the same as the AIN-93M feed. Table 1 shows the compounding table of each test formula. In each group, the test formula described above was freely ingested and reared for about 2 months, and autopsy was performed 58 days after the start of the test. The following items were measured during the breeding period and at the time of necropsy. Statistical analysis of the measurement results was performed by Student's t test using EXCEL.

<Measurement items during the trial period>

(A) Body weight, intake and feed: measured 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, 39, 43, 46, 50, 53, 57 days after the start of the test and the start of the test It was.

(B) Muscle mass and fat mass: measured by X-ray CT prior to the start of the test (6 days before the start of the test), mid-test (25 days after the start of the test), and late in the test (53 days after the start of the test). Specifically, the mouse is inhaled with isoprene (registered trademark) and Dainippon Seiyaku Co., Ltd. under anesthesia and an X-ray CT device (X-ray CT Rasita (registered trademark) LT-100 for a laboratory animal) is used under anesthesia. Muscle mass (g) and fat (visceral fat and subcutaneous fat) amount (g) were measured using KK. In addition, these values were divided by the weight at the time of measurement to determine relative muscle mass (g / g body weight) and relative fat mass (g / g body weight).

<Measurement Items at Autopsy>

Fat mass: The fat of peri testis, posterior peritoneum and mesentery was collected and its wet weight (g) was measured, and the value was divided by the weight to obtain a relative fat mass (g / g body weight).

Table 1 shows the compounding amount (g) per 100 kcal of each test formula. In addition, modified AIN-93M shown in Table 1 means the removal of corn starch and sucrose from AIN-93M which is a standard tablet feed for nutritional research in mice or rats published in 1993 from the US National Institute of Nutrition (AIN). AIN-93M, on the other hand, is the standard purified feed for mature animals that have passed the growing season.

(2) Results and Discussion

Body weight and average calorie intake: The results are shown in FIG. Body weight increased smoothly in both groups, and no significant difference was found between the groups. Average intake calories (kcal) during the test period by the following formula (Equation 1: AIN-93M feed and Equation 2: Xylitol-added AIN-93M feed) from the average intake (g / object, day) during the test period. / Object, day) was 12.7 and 12.3 kcal / object, day in the control group and Xyl group, respectively, were almost equivalent.

Average calorie intake (kcal / individual, daily) = Average intake (g / individual, daily) × 3.58 (kcal / g feed)

Average calorie intake (kcal / individual, day) = Average intake (g / individual, day) × 3.55 (kcal / g feed)

Relative muscle mass and relative fat mass: The results are shown in FIG. Relative muscle mass obtained from the results of X-ray CT did not differ before the start of the test, and the Xyl group tended to show a higher value than the control group as the breeding period progressed. At the end of the test, the Xyl group showed significantly higher values (p <0.05) than the control. The relative fat mass determined from the results of the X-ray CT did not differ before the start of the test, and the Xyl group tended to have a lower value than the control group as the breeding period progressed. At the end of the test, the Xyl group showed a significantly lower value (p <0.05) than the control.

Relative fat mass at autopsy: The results are shown in FIG. 3. The relative fat mass of the retroperitoneal and mesenteric tended to be lower in the Xyl group than in the control group. The relative fat mass around the testis was significantly lower (p <0.05) in the Xyl group than in the control group, and the same results as the X-ray CT measurements were obtained.

As described above, although the weight gain and calorie intake were equivalent, it was confirmed that the amount of fat accumulation in the Xyl group was significantly lower than that of the control group. It has been found that body fat accumulation can be suppressed by substituting Xyl for a part of the sugars in the mouse and rat tablet feed.

Example 2 (Measurement of Anti-fat Accumulation Effect of Palatinos)

(1) materials and methods

SD rats (male, 4 week old, 6 week old test start, n = 6 / group) were divided into groups to prepare palatinose and control groups. Removing corn starch and sucrose from AIN-93G (hereinafter also referred to as modified AIN-93G) 60% (w / w) and palatinose 40% (w / w) by mixing 40% palatinose added AIN-93G The group which produced the feed and provided it as a test formula was called the palatinose group. The control group was provided with 40% sucrose-added AIN-93G feed prepared by mixing 60% (w / w) of modified AIN-93G and 40% (w / w) of sucrose. Table 2 shows the compounding table of the test formula. In each group, the above-mentioned test formula was freely ingested and reared for about 2 months, and autopsy was performed 66 days after the test start date. The following items were measured during the breeding period and at the time of necropsy. Statistical analysis of the measurement results was performed by Student's t test using EXCEL.

<Measurement items during the trial period>

Body weight, intake and subsidy: 1, 2, 3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, 31, 34, 35, 36, 37 from test start date and test start date , 38, 41, 43, 45, 48, 50, 52, 55, 57, 59, 62, 64, 66 days later.

<Measurement Items at Autopsy>

Fat amount at autopsy: The fat in the peri testicular and posterior peritoneum was taken and its wet weight (g) was measured. In addition, the value was divided by the body weight to determine the relative fat mass (g / g body weight).

Table 2 shows the compounding amount (g) per 90.2 g of Test Formula. On the other hand, AIN-93G is a standard tablet feed for nutritional research in mice or rats published in 1993 by the National Institute of Nutrition (AIN), and is a standard tablet feed used in growing, gestational and lactation periods.

(2) Results and Discussion

Body weight and average calorie intake: The results are shown in FIG. 4. Body weight increased smoothly in both groups, and no significant difference was found between the groups. Average intake calories during the test period (g / object, day) from the following formula (Equation 3: 40% sucrose added AIN-93G feed and 40% palatinose added AIN-93g feed) kcal / individual, day) was calculated to be 72.9 and 69.9 kcal / rat / day in the control and palatinose groups, respectively, and were nearly equivalent.

Average calorie intake (kcal / individual, daily) = Average intake (g / individual, daily) × 3.77 (kcal / g feed)

Relative fat mass at autopsy: Results are shown in FIG. 5. The relative fat mass of the peri testicular and posterior peritoneum was significantly lower (p <0.01) in the Palatinos group than in the control group.

Thus, despite the weight gain and calorie intake equivalent, it was confirmed that the palatinose group was significantly lower in fat accumulation compared to the control group. It has been found that body fat accumulation can be suppressed by substituting part of the carbohydrate of mouse and rat tablets with palatinose.

Example 3 (Synergy of Xylitol and Palatinos)

(1) materials and methods

C57BL / 6 mice (male, 5 week old, 6 week old test start, n = 6 / group) were divided into groups to prepare Xyl (-) and Xyl (+) groups. The Xyl (+) group was provided with the feed shown in Table 3 as a test formula. In the Xyl (-) group, the feed shown in Table 4, in which xylitol included in the feed shown in Table 3 was replaced with dextrin, was provided as a test formula. In each group, the test formula described above was fed freely and reared for about two months, and autopsy was performed 60 days after the start of the test. The following items were measured during the breeding period and at the time of necropsy. Statistical analysis of the measurement results was performed by Student's t test using EXCEL.

<Measurement items during the trial period>

(A) Body weight: It was measured 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, 39, 43, 45, 49, 53, 57 days after the test start date and the test start date.

(B) Muscle mass and fat mass: measured by X-ray CT before the start of the test (6 days before the start of the test), during the test (28 days after the start of the test), and after the test (56 days after the start of the test). Specifically, the mouse is inhaled with isoprene (registered trademark) and Dainippon Seiyaku Co., Ltd. under anesthesia and an X-ray CT device (X-ray CT Rasita (registered trademark) LT-100 for a laboratory animal) is used under anesthesia. Muscle mass (g) and fat (visceral fat and subcutaneous fat) amount (g) were measured using KK. In addition, these values were divided by the weight at the time of measurement to determine relative muscle mass (g / g body weight) and relative fat mass (g / g body weight).

<Measurement Items at Autopsy>

Fat mass: The fat of peri testis, posterior peritoneum and mesentery was collected and its wet weight (g) was measured, and the value was divided by the weight to obtain a relative fat mass (g / g body weight).

(2) Results and Discussion

Body weight: The results are shown in FIG. Body weight increased smoothly in both groups, but after 43 days from the start of the test, the Xyl (+) group was found to be significantly lower (p <0.05) than the Xyl (-) group.

Relative muscle mass and relative fat mass: The results are shown in FIG. Relative muscle mass obtained from the results of X-ray CT was not significantly different between the two groups before the start of the test and in the middle of the test, but in the late test, the Xyl (+) group was significantly (p) for the Xyl (-) group. <0.05) high values were shown. The relative fat mass determined from the results of the X-ray CT was not different before the start of the test, and the Xyl (+) group tended to have a lower value than the Xyl (-) group as the breeding period progressed. At the end of the test, the Xyl group showed a significantly lower value (p <0.05) than the control.

Relative fat mass at autopsy: Results are shown in FIG. 8. In any of the peri testicular, posterior peritoneal and mesenteric fats, the Xyl (+) group showed significantly lower values than the Xyl (-) group (p <0.01: peri testicular, peritoneal and mesenteric fat) values, The same result as the X-ray CT measurement was obtained.

As described above, it was confirmed that the Xyl (+) group had significantly lower weight gain and fat accumulation and muscle mass than the Xyl (-) group. In addition, compared with the example of Example 1 (xylitol only) Example 2 (palatinose only), the fat accumulation inhibitory effect was remarkable. From this, it was found that the synergistic effect of xylitol and palatinose on the fat accumulation inhibition was great.

Example 4 (Measurement of Body Fat Accumulation Inhibition Effect by Xylitol and Palatinos)

(1) materials and methods

After the C57BL / 6 mice (male, 6-week-old test start) were environmentally purified, their weight was divided into 6 groups of 6 animals in each group as indicators, and the test formula shown in Table 5 was freely ingested by the animals of each group. The breeding was carried out by the test formula for about two months as the test start date. Animals were fasted overnight 59 days after the start of the test and autopsied 60 days after the start of the test. In any period, water was taken freely. The following items were measured during the breeding period and at the time of necropsy. Statistical analysis of the measurement results was carried out using statistical soft Stat Light (Yunkx Co., Ltd.), and the test was conducted by a Tuki-Crammer multiple comparison test.

<Measurement items during the trial period>

(A) Body weight: It was measured 4, 8, 10, 14, 18, 22, 25, 28, 32, 36, 39, 43, 46, 50, 53, 56, 59 days after the test start date and the test start date.

Intake amount, intake amount: In the same way as the weight measurement, the remaining feed and the remaining amount was measured to calculate the intake amount and the amount of intake.

(B) Muscle mass and fat mass: X-ray CT before the start of the test (7 or 6 days before the start of the test), mid-test (28 or 29 days after the start of the test), and late in the test (56 or 57 days after the start of the test) Measured by Specifically, the mouse is inhaled with isoprene (registered trademark) and Dainippon Seiyaku Co., Ltd. under anesthesia and an X-ray CT device (X-ray CT Rasita (registered trademark) LT-100 for a laboratory animal) is used under anesthesia. Muscle mass (g) and fat (visceral fat and subcutaneous fat) amount (g) were measured using KK. In addition, these values were divided by the weight at the time of measurement to determine relative muscle mass (g / g body weight) and relative fat mass (g / g body weight).

<Measurement Items at Autopsy>

Fat mass: The fat of peri testis, posterior peritoneum and mesentery was collected and its wet weight (g) was measured, and the value was divided by the weight to obtain a relative fat mass (g / g body weight).

Organ weight: The pancreas, liver, spleen and kidney were removed and their wet weight (g) was measured. In addition, the value was divided by the body weight to determine the relative organ weight (g / g body weight).

Group configuration and test formula are shown in Table 5. Here, the compounding quantity (g) per 27.9 g of each test formula is shown. In addition, modified AIN-93M shown in Table 5 means the removal of corn starch and fructose from AIN-93M which is a standard refined feed for nutritional research in mice and rats published in 1993 from the US National Institute of Nutrition (AIN). AIN-93M, on the other hand, is a standard tablet feed for mature animals that have undergone growth. Either test diet is in powder feed.

(2) Results and Discussion

Body weight: The results are shown in FIG. Body weight increased smoothly in each group. Significant differences were observed between the combined high dose group and the control group 56 days after the start of the test, but since only 1 day was found in the significant difference, it was judged that the test formula had no effect on the weight change throughout the test period.

Intake: The results are shown in Table 6.

In Table 6, each intake was calculated by the following equation (4).

No significant difference was found between the groups in the total intake per mouse during the trial period. In addition, no significant difference was found between the groups with respect to the average intake calories obtained from the daily intake, intake, and calories per g of the feed per mouse during the test period.

Muscle mass and fat mass: The results are shown in FIG.

In FIG. 10, the order of "1 control group" to "6 combination high dose group" displayed on the right side corresponds to the order from "1 control group" at the left end of the graph to the "6 combination high dose group" at the right end. The same applies to FIGS. 11 to 13.

In the relative muscle mass obtained by X-ray CT, no significant difference was found between the groups before the test, but the xylitol low dose group (p <0.05), the combined low dose group (p <0.05), and high xylitol during the test period The group (p <0.05) and the combined high dose group (p <0.01) showed significantly higher values than the control group. In the late test period, the combination high dose group (p <0.01) showed a significantly higher value than the control group.

X-ray CT showed no significant difference between the groups before the test, but the Xylitol low dose group (p <0.05), combined low dose group (p <0.05), and high xylitol high dose groups (p <0.05) and the combination high dose group (p <0.01) showed significantly lower values than the control group. In the late test period, the combination high dose group (p <0.01) showed a significantly lower value than the control group.

Relative organ weight at necropsy: No organs could identify significant differences between groups.

Relative fat mass at necropsy: The results are shown in FIG. 11 (peri testis), FIG. 12 (mesentery), and FIG. 13 (peritoneal membrane). As shown in FIG. 11, the relative fat mass around the testis showed a lower value in the whole group than the control group compared to the control group, and a significant difference was observed in the combined high dose group (p <0.05).

As shown in FIG. 12, the relative fat mass of the posterior peritoneum was lower in the whole group than the control group compared to the control group, and the combination low-dose group (p <0.05), xylitol high-dose group (p <0.05) and the combination Significant differences were observed in the high dose group (p <0.01).

As shown in FIG. 13, the relative fat mass of the mesentery showed a lower value in the whole group than the control group compared to the control group, and a significant difference was observed in the combined low dose group (p <0.05) and the combined high dose group (p <0.01). .

As described above, no difference was found between the groups in the weight trend, calorie intake and relative organ weight. Significantly lower values were found in xylitol and the combination group in muscle mass and fat mass per body weight or in three types of fat weight at necropsy, and a tendency of low values was found in the palatinose group. In particular, in the combination high dose group containing 7.00 g of palatinose and 0.90 g of xylitol in test formula 27.9 g, compared to the combination low dose group containing 7.00 g of palatinose and 0.45 g of xylitol in test formula 27.9 g. The synergistic effects of palatinose and xylitol were remarkable.

Since the composition for antifat accumulation of the present invention has an antifat accumulation effect, it can be applied as a medicine or food and drink having the same function.

Claims (11)

An anti-fat accumulation composition containing a sugar alcohol. The anti-fat accumulation composition according to claim 1, which contains oligosaccharides. The anti-fat accumulation composition according to claim 2, wherein the oligosaccharide is heterooligosaccharide. The composition for anti-fat accumulation according to claim 3, wherein the heterooligosaccharide is a sucrose structural isomer. The anti-fat accumulation composition according to any one of claims 2 to 4, wherein the sucrose structural isomer is palatinose. The composition for anti-fat accumulation according to any one of claims 2 to 5, wherein the sugar alcohol and the oligosaccharide are contained in a weight ratio of 1: 3 to 1:20. The anti-fat accumulation composition according to any one of claims 1 to 6, wherein the sugar alcohol is xylitol. A pharmaceutical for fat accumulation prevention and / or treatment comprising the anti-fat accumulation composition according to any one of claims 1 to 7 as an active ingredient. A food and drink for preventing and / or treating fat accumulation, comprising the anti-fat accumulation composition according to any one of claims 1 to 7. Use of the anti-fat accumulation composition according to any one of claims 1 to 7 for the manufacture of a pharmaceutical product for fat accumulation and / or treatment or a food and drink for fat accumulation prevention and / or treatment. A fat accumulation prevention and / or treatment method by administering the anti-fat accumulation composition according to any one of claims 1 to 7.

Images